Navigation Links
'Phase 0' Trials Aim to Speed Cancer Drug Development
Date:4/17/2009

Report on first such study involves effort to improve chemotherapy effectiveness

FRIDAY, April 17 (HealthDay News) -- Even after years of painstaking research and testing, only a small percentage of cancer agents make it from the laboratory to the patient. So scientists have come up with a way to weed out the duds earlier in the process and speed good medications to the marketplace.

The new model, a so-called "phase 0" clinical trial, promises to streamline the costly and time-consuming drug development process, helping to deliver good drugs to people who need them more quickly.

"We want to find out if they're ineffective in the smallest number of patients and get definitive information as early in the development process as possible," said Dr. James H. Doroshow, director of the division of cancer treatment and diagnosis at the National Cancer Institute in Bethesda, Md.

As the name implies, a phase 0 trial precedes "phase I" testing, traditionally the first step in the process of human drug testing. In a phase I study, the goal is to determine the best way to administer a drug and the maximum dose tolerated with the fewest side effects.

Phase 0 studies expose a small number of people to low doses of a drug over a limited period of time -- seven days or less. Scientists look at how the body reacts to the drug and how it acts in the body. If the drug hits its intended target without producing significant side effects, the next phase can be expedited. If not, a decision can be made to scrap the drug before it goes on to further, more costly development and testing.

"It may help accelerate clinical drug development in oncology because you're able to theoretically get the drug into man faster and learn more about the drug in man earlier," explained Dr. Patricia M. LoRusso, director of the phase I clinical-pharmacology team at the Barbara Ann Karmanos Cancer Institute in Detroit.

A mere 5
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Phase 0' Trials Aim to Speed Cancer Drug Development
(Date:5/18/2013)... Orlando, FL (May 18, 2013) There are ... procedures commonly used to diagnose or treat gastrointestinal ... Week (DDW). , A study by New ... that more objective testing may substantially reduce the ... (GERD). Although GERD is believed to affect nearly ...
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... After working diligently for months and putting in ... the integration of the fitment specs for the redesigned 2012 ... stun the automobile market with its extraordinary features and unique ... as the latest entry in the size it up ... the year 2013. , Aptly suiting its name, 2012 ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Although obesity ... tumors, the association between obesity and esophageal adenocarcinoma, a ... other obesity-related tumors. As reported on Cancer.gov, ... are almost twice as likely as those of normal ... the relationship between obesity and esophageal cancer is not ...
(Date:5/18/2013)... Show And Go Training, the culmination of Eric ... that is all about is getting results in the fastest ... http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting an investigative review. , ... phase system” designed to make you faster, stronger, fitter and ... out in the gym. The training manual and exercise video ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... of,Gujarat in India is now slowly coming to terms ... channels and papers are busy increasing the,death toll by ... and,the central government are now faced with the unenviable ... crammed with patients and doctors are,desperately needed in most ...
... were more likely to have an eating disorder when ... used to take less than their prescribed dose of ... insulin lead to early onset of diabetes related complications ... damage. Intensive treatment to diabetes could be the risk ...
... path breaking idea researchers at the just concluded Indian science ... with agricultural scientists to combat anemia with iron fortification of ... years of age are anemic in India. While iron supplementation ... in turn to fight anemia in people is fairly cheaper, ...
... blocked the related tissue experiences ischemia, a state of low ... as Ichemia / Reperfusion (IR) injury occurs during heart attacks. ... new drugs to save the damaged tissue and treat heart ... –1) level increases and acts like a common link between ...
... the New Year elbowing out the old year it is time ... work of 2000. And when we do that the first and ... of the genetic code. Almost all the top ten lists released ... remarkable feat in a prominent place and a majority of them ...
... the United States of America, a lawyer- Peter Angelos, who ... in Maryland, has announced that he is dragging Vodafone to ... to cell phone users who are said to have developed ... This case has raised eyebrows not only because of the ...
Cached Medicine News:Health News:Doctors needed urgently in Gujarat 2Health News:Doctors needed urgently in Gujarat 3Health News:Doctors needed urgently in Gujarat 4
(Date:5/17/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ), ... healthcare and to first responders on the federal, state ... the fiscal 2013 fourth quarter and year ended January ... market close and will conduct a conference call on ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... NEW YORK, Feb. 27, 2012 Delcath Systems, Inc., ... first patients in Germany have been treated with the ... Johann Wolfgang Goethe University Hospital, a premier European cancer treatment ... as part of the initial launch and training agreement ...
...  Osseon ® Therapeutics, Inc. announced today that ... Agreement with Aesculap AG to distribute its vertebral ... CE-Mark approved device – Osseoflex ® SB ... Asia.  Aesculap is a division of B. Braun ...
Cached Medicine Technology:Delcath Announces First CHEMOSAT Procedures in Germany 2Delcath Announces First CHEMOSAT Procedures in Germany 3Delcath Announces First CHEMOSAT Procedures in Germany 4Osseon® Announces International Distribution Agreement with Aesculap 2
... high gel strength, high electrophoretic mobility, ... agarose is the superior choice for ... remain easy to handle at concentrations ... shorter run times. Low background staining ...
... This new general-purpose agarose, like the ... quality tested (GQT) grade. This ensures that ... be manipulated without compromising quality. Certified molecular ... a very high molecular weight, resulting in ...
... of a set of reagents and instruments ... in hospital immunohematology labs and blood transfusion ... solutions in robotics, fluidics or the analysis ... monoclonal antibodies and the human antiglobulin reagents ...
A custom blend for Applied Biosystems by FMC. Designed specifically for the electrophoresis of PCR products....
Medicine Products: